Strobl J S, Kirkwood K L, Lantz T K, Lewine M A, Peterson V A, Worley J F
Department of Pharmacology and Toxicology, West Virginia University Health Sciences Center, Morgantown 26506.
Cancer Res. 1990 Sep 1;50(17):5399-405.
Permanent cell culture lines derived from human breast cancer tissue are important experimental models in the study of human breast cancer cell proliferation. In the present work, pimozide, thioridazine, W-13, and W-12 were shown to inhibit MCF-7 human breast cancer cell growth. The 50% inhibition concentration values determined in two proliferation assays, [3H]thymidine incorporation and cell number, were in close agreement for each compound tested. The order of potency for growth inhibition in the presence of 2% stripped calf serum was pimozide (Ki 2 microM) greater than thioridazine (Ki 5 microM) greater than W-13 (Ki 15 microM) greater than W-12 (Ki 39 microM). Similar concentrations of these compounds blocked estradiol-induced growth of MCF-7 cells, but estrogen receptor (ER) interactions do not seem to be involved. Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of progesterone receptors by estradiol. Furthermore, pimozide also inhibited incorporation of [3H]thymidine into MCF-7 cells stimulated by polypeptide hormones in serum-free medium. The Ki for pimozide in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), insulin-like growth factor I (0.54 microM), and epidermal growth factor (0.43 microM). The effects of pimozide on breast cancer cell growth were not limited to the MCF-7 cell line. Pimozide also blocked cell growth and [3H]thymidine incorporation into the ER-positive T47D and ZR75-1B human breast cancer cell lines and the ER-negative human breast cancer cell line, MDA-MB-231. Although numerous mechanisms of action of pimozide and thioridazine have been identified, both drugs are calmodulin antagonists at drug concentrations that inhibit breast cancer cell growth in vitro. Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide. We conclude that pimozide and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and ER-negative human breast tumors.
源自人乳腺癌组织的永久细胞系是研究人乳腺癌细胞增殖的重要实验模型。在本研究中,已证明匹莫齐特、硫利达嗪、W - 13和W - 12可抑制MCF - 7人乳腺癌细胞生长。在两种增殖试验([³H]胸腺嘧啶核苷掺入法和细胞计数法)中测定的每种受试化合物的50%抑制浓度值非常接近。在含2%脱脂小牛血清的情况下,生长抑制效力顺序为匹莫齐特(Ki 2微摩尔)大于硫利达嗪(Ki 5微摩尔)大于W - 13(Ki 15微摩尔)大于W - 12(Ki 39微摩尔)。这些化合物的类似浓度可阻断雌二醇诱导的MCF - 7细胞生长,但似乎不涉及雌激素受体(ER)相互作用。匹莫齐特和硫利达嗪对MCF - 7 ER的雌二醇结合特性无影响,匹莫齐特也不干扰雌二醇对孕激素受体的诱导。此外,匹莫齐特还抑制无血清培养基中多肽激素刺激的MCF - 7细胞中[³H]胸腺嘧啶核苷的掺入。单独无血清培养基中匹莫齐特的Ki为0.46微摩尔,与在胰岛素(0.42微摩尔)、胰岛素样生长因子I(0.54微摩尔)和表皮生长因子(0.43微摩尔)存在下测定的结果相似。匹莫齐特对乳腺癌细胞生长的影响不限于MCF - 7细胞系。匹莫齐特还可阻断ER阳性的T47D和ZR75 - 1B人乳腺癌细胞系以及ER阴性人乳腺癌细胞系MDA - MB - 231的细胞生长和[³H]胸腺嘧啶核苷掺入。尽管已确定了匹莫齐特和硫利达嗪的多种作用机制,但在体外抑制乳腺癌细胞生长的药物浓度下,这两种药物都是钙调蛋白拮抗剂。选择性钙调蛋白拮抗剂W - 13和W - 12对MCF - 7细胞生长的抑制作用与钙调蛋白拮抗作用在匹莫齐特广泛的生长抑制特性中的作用一致。我们得出结论,匹莫齐特和硫利达嗪可能有助于控制雌二醇和多肽激素诱导的ER阳性和ER阴性人乳腺肿瘤的生长。